Baker Bros. Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Baker Bros. Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-152,964	Closed	-$1.57M	–	132
2016 Q4	$1.57M	Sell	152,964 -164,012	-52%	-$1.5M	0.02%	97
2016 Q3	$3.21M	Sell	316,976 -153,082	-33%	-$1.67M	0.03%	79
2016 Q2	$5.28M	Sell	470,058 -25,850	-5%	-$329K	0.06%	71
2016 Q1	$6.77M	Hold	495,908	–	–	0.07%	67
2015 Q4	$9.41M	Hold	495,908	–	–	0.08%	62
2015 Q3	$9.31M	Hold	495,908	–	–	0.09%	64
2015 Q2	$7.38M	Hold	495,908	–	–	0.06%	70
2015 Q1	$7.51M	Sell	495,908 -9,510	-2%	-$133K	0.06%	67
2014 Q4	$6.73M	Buy	505,418 +53,922	+12%	+$696K	0.07%	65
2014 Q3	$5.69M	Buy	451,496 +52,696	+13%	+$511K	0.07%	58
2014 Q2	$4.03M	Buy	+398,800	New	+$3.85M	0.05%	77

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baker Bros. Advisors's CNCE Position: Q1 2017 in Review

Baker Bros. Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 152,964 shares — an estimated $1.57M sold.

Baker Bros. Advisors first reported a position in CNCE in Q2 2014 and held it in 11 quarters. The position peaked at $9.41M in Q4 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Baker Bros. Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Baker Bros. Advisors sold 152,964 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.57M.
Baker Bros. Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 11 quarters.
Baker Bros. Advisors's Concert Pharmaceuticals, Inc. position peaked at $9.41M in Q4 2015.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.